CL2008002084A1 - Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas - Google Patents

Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas

Info

Publication number
CL2008002084A1
CL2008002084A1 CL2008002084A CL2008002084A CL2008002084A1 CL 2008002084 A1 CL2008002084 A1 CL 2008002084A1 CL 2008002084 A CL2008002084 A CL 2008002084A CL 2008002084 A CL2008002084 A CL 2008002084A CL 2008002084 A1 CL2008002084 A1 CL 2008002084A1
Authority
CL
Chile
Prior art keywords
thiochroman
chroman
tetrahydronaphthalene
benzenesulfonyl
pharmaceutical composition
Prior art date
Application number
CL2008002084A
Other languages
English (en)
Inventor
Ruo Xu
Wen-Lian Wu
Hongmei Li
Thavalakulamgara K Sasikumar
Duane Burnett
Theodros Asberom
Hubert B Josien
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2008002084A1 publication Critical patent/CL2008002084A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composición farmacéutica; y su uso para tratar enfermedades neurodegenerativas.
CL2008002084A 2007-07-17 2008-07-15 Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas CL2008002084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95016007P 2007-07-17 2007-07-17

Publications (1)

Publication Number Publication Date
CL2008002084A1 true CL2008002084A1 (es) 2009-01-23

Family

ID=39831616

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002084A CL2008002084A1 (es) 2007-07-17 2008-07-15 Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas

Country Status (13)

Country Link
US (1) US8618123B2 (es)
EP (1) EP2178882B1 (es)
JP (1) JP5204227B2 (es)
KR (1) KR20100044840A (es)
CN (1) CN101970445A (es)
AR (1) AR067560A1 (es)
AU (1) AU2008276492A1 (es)
CA (1) CA2693216A1 (es)
CL (1) CL2008002084A1 (es)
PE (1) PE20090447A1 (es)
TW (1) TW200904447A (es)
WO (1) WO2009011851A1 (es)
ZA (1) ZA201000191B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
US9226927B2 (en) 2011-09-09 2016-01-05 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
US9493484B2 (en) 2012-02-08 2016-11-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
KR102114536B1 (ko) * 2015-05-07 2020-05-22 브리스톨-마이어스 스큅 컴퍼니 RORγ 조정제로서의 트리시클릭 술폰
EA201991128A1 (ru) * 2016-11-09 2019-10-31 ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN111004198B (zh) * 2019-12-24 2023-03-28 瑞安宝源化工有限公司 一种苯并吡喃衍生物的合成方法
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
CN1304390C (zh) 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
KR20060013404A (ko) 2003-05-16 2006-02-09 머크 샤프 앤드 돔 리미티드 γ-세크레타제 억제용 사이클릭 설폰아미드
MX2008009414A (es) * 2006-01-20 2008-10-01 Schering Corp Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa.
TW200813054A (en) * 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
CN101754960A (zh) 2007-07-05 2010-06-23 先灵公司 四氢吡喃并色烯γ-分泌酶抑制剂

Also Published As

Publication number Publication date
JP2010533713A (ja) 2010-10-28
KR20100044840A (ko) 2010-04-30
JP5204227B2 (ja) 2013-06-05
US8618123B2 (en) 2013-12-31
TW200904447A (en) 2009-02-01
EP2178882A1 (en) 2010-04-28
CN101970445A (zh) 2011-02-09
AU2008276492A1 (en) 2009-01-22
US20110110948A1 (en) 2011-05-12
ZA201000191B (en) 2011-06-29
WO2009011851A1 (en) 2009-01-22
PE20090447A1 (es) 2009-04-18
AR067560A1 (es) 2009-10-14
AU2008276492A2 (en) 2010-02-18
EP2178882B1 (en) 2013-04-17
CA2693216A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CL2007003212A1 (es) Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY31922A (es) Compuestos
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008001835A1 (es) Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias